Skip to content
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
Menu
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact
Menu
  • About us
  • Our focus
  • Case studies
  • Our people
  • Our portfolio
  • Contact

Author name: Dev 1

Catalyst Biosciences

Public / Dev 1

Pharmaceutical

Catalyst Biosciences Read More »

Glycomimetics

Public / Dev 1

Biotech

Glycomimetics Read More »

Paratek

Exited, Public, Selected / Dev 1

Biotech

Paratek Read More »

Modus

Public / Dev 1

Biotech

Modus Read More »

Destiny Pharma

Public, Selected / Dev 1

Biotech

Destiny Pharma Read More »

Aprea

Public, Selected / Dev 1

Pharmaceutical

Aprea Read More »

Biosergen

Public / Dev 1

Biotech

Biosergen Read More »

Veloxis

Exited / Dev 1

Pharmaceutical

Veloxis Read More »

NovImmune

Exited, Selected / Dev 1

Pharmaceutical

NovImmune Read More »

Topigen

Exited / Dev 1

Biotech

Topigen Read More »

← Previous 1 2 3 4 Next →
Terms & conditions
Cookie policy
Privacy policy

Registered in England No. 3941653 | VAT No. GB 765 3567 96

© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority

Website by Instinctif Partners

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Rosetta Capital
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.